Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.37 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.37 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.37 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29563554 | 1.00 | KDM4E (0.40) | KDM4ESMN1; SMN2CFTRMAPK14CA12 | |
| SCHEMBL22832518 | 0.88 | KDM4E (0.40) | KDM4ESMN1; SMN2CFTRMAPK14CA12 | |
| SCHEMBL10020940 | 0.88 | MAOB (0.39) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL24965982 | 0.88 | EPHX2 (0.41) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL190082 | 0.87 | DGAT1 (0.44) | CDK1ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL22855238 | 0.86 | KDM4E (0.43) | KDM4ESMN1; SMN2CFTRMAPK14CA12 | |
| SCHEMBL29644326 | 0.86 | GAA (0.44) | KDM4ESMN1; SMN2CDK1ABCC9ABCC8 | |
| SCHEMBL2411518 | 0.86 | GAA (0.44) | KDM4ESMN1; SMN2CDK1ABCC9ABCC8 | |
| SCHEMBL582706 | 0.85 | POLB (0.44) | KDM4ESMN1; SMN2ABCC9ABCC8KCNJ11 | |
| SCHEMBL12321278 | 0.83 | NPC1 (0.39) | SMN1; SMN2MAPK14ABCC9ABCC8KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113698310-B | Preparation method of enzalutamide diester intermediate | 江西金丰药业有限公司 | 2023-03-17 | — | — | CN | claimed |
| CN-113698310-A | Preparation method of enzalutamide diester intermediate | 江西金丰药业有限公司 | 2021-11-26 | — | — | CN | claimed |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250129088-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | GAN & LEE PHARMACEUTICALS CO., LTD. (CN) | 2025-04-24 | — | — | US | disclosed |
| WO-2024097775-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024073626-A2 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024073626-A2 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2023143589-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | 甘李药业股份有限公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-113698310-B | Preparation method of enzalutamide diester intermediate | 江西金丰药业有限公司 | 2023-03-17 | — | — | CN | disclosed |
| EP-3527556-B1 | METHOD FOR PREPARING DEUTERATED IMIDAZOLE DIKETONE COMPOUND | HINOVA PHARMACEUTICALS INC (CN) | 2023-01-25 | — | — | EP | disclosed |
| US-20220242829-A1 | PROCESS FOR PREPARATION OF ENZALUTAMIDE | SYNTHON B.V. (NL) | 2022-08-04 | — | — | US | disclosed |
| CN-108976171-B | Compounds, compositions and their use in the manufacture of medicaments | 长沙泽达医药科技有限公司 | 2020-06-16 | — | — | CN | disclosed |
| US-10626091-B2 | Process for the preparation of enzalutamide | LAURUS LABS LIMITED (IN) | 2020-04-21 | — | — | US | disclosed |
| US-20200087261-A1 | METHOD FOR PREPARING DEUTERATED IMIDAZOLE DIKETONE COMPOUND | HINOVA PHARMACEUTICALS INC. (CN) | 2020-03-19 | — | — | US | disclosed |
| WO-2020042622-A1 | COMPOUND, COMPOSITION, AND USE THEREOF IN PREPARATION OF DRUG | 长沙泽达医药科技有限公司 | 2020-03-05 | — | — | WO | disclosed |
| EP-3527556-A1 | METHOD FOR PREPARING DEUTERATED IMIDAZOLE DIKETONE COMPOUND | Hinova Pharmaceuticals Inc. (CN) | 2019-08-21 | — | — | EP | disclosed |
| EP-3527556-A1 | METHOD FOR PREPARING DEUTERATED IMIDAZOLE DIKETONE COMPOUND | Hinova Pharmaceuticals Inc. (CN) | 2019-08-21 | — | — | EP | disclosed |
| US-20190127332-A1 | PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | LAURUS LABS LIMITED (IN) | 2019-05-02 | — | — | US | disclosed |
| US-20170313662-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | LAURUS LABS LIMITED (IN) | 2017-11-02 | — | — | US | disclosed |
| WO-2016051423-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | LAURUS LABS PRIVATE LIMITED (IN) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129088-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | CRBN, UBE3A, UBE3C | KDM4E 1439/4885SMN1; SMN2 2278/4885CFTR 2338/4885 |
| US-20170313662-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | KLK4, KLK5, KLK1 | KDM4E 182/4885SMN1; SMN2 1830/4885CFTR 4701/4885 |
| US-20190127332-A1 | PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | KLK4, KLK5, KLK1 | KDM4E 183/4885SMN1; SMN2 2150/4885CFTR 4726/4885 |
| US-10626091-B2 | Process for the preparation of enzalutamide | KLK4, KLK5, KLK1 | KDM4E 183/4885SMN1; SMN2 2150/4885CFTR 4726/4885 |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR5A2, NR3C1 | KDM4E 3467/4885SMN1; SMN2 3659/4885CFTR 2967/4885 |
| US-20220242829-A1 | PROCESS FOR PREPARATION OF ENZALUTAMIDE | AR, CYP17A1, HSD11B1 | KDM4E 298/4885SMN1; SMN2 2740/4885CFTR 2890/4885 |
| US-20200087261-A1 | METHOD FOR PREPARING DEUTERATED IMIDAZOLE DIKETONE COMPOUND | DEK, BCKDK, DHPS | KDM4E 401/4885SMN1; SMN2 4657/4885CFTR 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.